Cardiac beta1-adrenoceptor autoantibodies in human heart disease:
rationale and design of the Etiology, Titre-Course, and Survival
(ETiCS) Study
N. Deubner, D. Berliner, A. Schlipp, G. Gelbrich, A. Caforio, S. Felix, M. Fu, H. Katus, C. Angermann, M. Lohse, G. Ertl, S. Stork, und R. Jahns. Eur J Heart Fail, 12 (7):
753-62(Juli 2010)Deubner, Nikolas Berliner, Dominik Schlipp, Angela Gelbrich, Gotz
Caforio, Alida L P Felix, Stephan B Fu, Michael Katus, Hugo Angermann,
Christiane E Lohse, Martin J Ertl, Georg Stork, Stefan Jahns, Roland
Etiology, Titre-Course, and Survival-Study Group Research Support,
Non-U.S. Gov't Netherlands European journal of heart failure : journal
of the Working Group on Heart Failure of the European Society of
Cardiology Eur J Heart Fail. 2010 Jul;12(7):753-62. Epub 2010 May
21..
Zusammenfassung
AIMS: Evidence for a pathophysiologic relevance of autoimmunity in
human heart disease has substantially increased over the past years.
Conformational autoantibodies stimulating the cardiac beta1-adrenoceptor
(beta1-aabs) are considered of importance in heart failure development
and clinical pilot studies have shown their prognostic significance
in human 'idiopathic' cardiomyopathy. METHODS: We recently developed
a novel highly sensitive fluorescence-based functional assay to detect
stimulating beta1-aabs. We will use this method to assess Etiology,
Titre-Course, and effect on Survival (ETiCS) of beta1-aabs in a prospective
multicentre study with serial follow-up of patients after a first
acute myocarditis or myocardial infarction. Several European core
laboratories will jointly study the hypothesis that both disorders
may trigger autoimmune reactions leading to the generation of beta1-aabs
and/or other heart-directed aabs. Further, sera from healthy controls
and well-characterized patient cohorts with dilated, ischaemic, or
hypertensive cardiomyopathy will be analysed retrospectively for
beta1-aab prevalence, incidence, persistence, and/or clearance. CONCLUSION:
ETiCS is so far the largest clinical diagnostic study projected to
address cardiac autoimmunity. It attempts to unravel the pathophysiology
of cardiac autoantibody formation and persistence/clearance. ETiCS
will enhance current knowledge on autoimmunity in human heart disease
and promote endeavours to develop novel therapies targeting cardiac
aabs.
Deubner, Nikolas Berliner, Dominik Schlipp, Angela Gelbrich, Gotz
Caforio, Alida L P Felix, Stephan B Fu, Michael Katus, Hugo Angermann,
Christiane E Lohse, Martin J Ertl, Georg Stork, Stefan Jahns, Roland
Etiology, Titre-Course, and Survival-Study Group Research Support,
Non-U.S. Gov't Netherlands European journal of heart failure : journal
of the Working Group on Heart Failure of the European Society of
Cardiology Eur J Heart Fail. 2010 Jul;12(7):753-62. Epub 2010 May
21.
%0 Journal Article
%1 Deubner2010
%A Deubner, N.
%A Berliner, D.
%A Schlipp, A.
%A Gelbrich, G.
%A Caforio, A. L.
%A Felix, S. B.
%A Fu, M.
%A Katus, H.
%A Angermann, C. E.
%A Lohse, M. J.
%A Ertl, G.
%A Stork, S.
%A Jahns, R.
%D 2010
%J Eur J Heart Fail
%K *Research Antibody Autoantibodies/*immunology Autoimmunity/*immunology Cardiomyopathy, Design Dilated/*immunology Humans Immunoassay/methods Infarction/*immunology Multicenter Myocardial Myocarditis/*immunology Myocardium/*immunology Patient Selection Specificity/immunology Studies Topic as beta-1/*immunology Receptor Adrenergic
%N 7
%P 753-62
%T Cardiac beta1-adrenoceptor autoantibodies in human heart disease:
rationale and design of the Etiology, Titre-Course, and Survival
(ETiCS) Study
%U http://www.ncbi.nlm.nih.gov/pubmed/20494925
%V 12
%X AIMS: Evidence for a pathophysiologic relevance of autoimmunity in
human heart disease has substantially increased over the past years.
Conformational autoantibodies stimulating the cardiac beta1-adrenoceptor
(beta1-aabs) are considered of importance in heart failure development
and clinical pilot studies have shown their prognostic significance
in human 'idiopathic' cardiomyopathy. METHODS: We recently developed
a novel highly sensitive fluorescence-based functional assay to detect
stimulating beta1-aabs. We will use this method to assess Etiology,
Titre-Course, and effect on Survival (ETiCS) of beta1-aabs in a prospective
multicentre study with serial follow-up of patients after a first
acute myocarditis or myocardial infarction. Several European core
laboratories will jointly study the hypothesis that both disorders
may trigger autoimmune reactions leading to the generation of beta1-aabs
and/or other heart-directed aabs. Further, sera from healthy controls
and well-characterized patient cohorts with dilated, ischaemic, or
hypertensive cardiomyopathy will be analysed retrospectively for
beta1-aab prevalence, incidence, persistence, and/or clearance. CONCLUSION:
ETiCS is so far the largest clinical diagnostic study projected to
address cardiac autoimmunity. It attempts to unravel the pathophysiology
of cardiac autoantibody formation and persistence/clearance. ETiCS
will enhance current knowledge on autoimmunity in human heart disease
and promote endeavours to develop novel therapies targeting cardiac
aabs.
@article{Deubner2010,
abstract = {AIMS: Evidence for a pathophysiologic relevance of autoimmunity in
human heart disease has substantially increased over the past years.
Conformational autoantibodies stimulating the cardiac beta1-adrenoceptor
(beta1-aabs) are considered of importance in heart failure development
and clinical pilot studies have shown their prognostic significance
in human 'idiopathic' cardiomyopathy. METHODS: We recently developed
a novel highly sensitive fluorescence-based functional assay to detect
stimulating beta1-aabs. We will use this method to assess Etiology,
Titre-Course, and effect on Survival (ETiCS) of beta1-aabs in a prospective
multicentre study with serial follow-up of patients after a first
acute myocarditis or myocardial infarction. Several European core
laboratories will jointly study the hypothesis that both disorders
may trigger autoimmune reactions leading to the generation of beta1-aabs
and/or other heart-directed aabs. Further, sera from healthy controls
and well-characterized patient cohorts with dilated, ischaemic, or
hypertensive cardiomyopathy will be analysed retrospectively for
beta1-aab prevalence, incidence, persistence, and/or clearance. CONCLUSION:
ETiCS is so far the largest clinical diagnostic study projected to
address cardiac autoimmunity. It attempts to unravel the pathophysiology
of cardiac autoantibody formation and persistence/clearance. ETiCS
will enhance current knowledge on autoimmunity in human heart disease
and promote endeavours to develop novel therapies targeting cardiac
aabs.},
added-at = {2010-12-14T18:12:02.000+0100},
author = {Deubner, N. and Berliner, D. and Schlipp, A. and Gelbrich, G. and Caforio, A. L. and Felix, S. B. and Fu, M. and Katus, H. and Angermann, C. E. and Lohse, M. J. and Ertl, G. and Stork, S. and Jahns, R.},
biburl = {https://www.bibsonomy.org/bibtex/2c401fafdb01fa91763c89df711e54c37/pharmawuerz},
endnotereftype = {Journal Article},
groups = {private},
interhash = {aecb0fa66838c96717ef5d45e7625195},
intrahash = {c401fafdb01fa91763c89df711e54c37},
issn = {1879-0844 (Electronic) 1388-9842 (Linking)},
journal = {Eur J Heart Fail},
keywords = {*Research Antibody Autoantibodies/*immunology Autoimmunity/*immunology Cardiomyopathy, Design Dilated/*immunology Humans Immunoassay/methods Infarction/*immunology Multicenter Myocardial Myocarditis/*immunology Myocardium/*immunology Patient Selection Specificity/immunology Studies Topic as beta-1/*immunology Receptor Adrenergic},
month = Jul,
note = {Deubner, Nikolas Berliner, Dominik Schlipp, Angela Gelbrich, Gotz
Caforio, Alida L P Felix, Stephan B Fu, Michael Katus, Hugo Angermann,
Christiane E Lohse, Martin J Ertl, Georg Stork, Stefan Jahns, Roland
Etiology, Titre-Course, and Survival-Study Group Research Support,
Non-U.S. Gov't Netherlands European journal of heart failure : journal
of the Working Group on Heart Failure of the European Society of
Cardiology Eur J Heart Fail. 2010 Jul;12(7):753-62. Epub 2010 May
21.},
number = 7,
pages = {753-62},
shorttitle = {Cardiac beta1-adrenoceptor autoantibodies in human heart disease:
rationale and design of the Etiology, Titre-Course, and Survival
(ETiCS) Study},
timestamp = {2010-12-14T18:22:39.000+0100},
title = {Cardiac beta1-adrenoceptor autoantibodies in human heart disease:
rationale and design of the Etiology, Titre-Course, and Survival
(ETiCS) Study},
url = {http://www.ncbi.nlm.nih.gov/pubmed/20494925},
volume = 12,
year = 2010
}